Cabergoline-Induced Psychosis in a Patient With Undiagnosed Depression

Abstract

Back to table of contents Previous article Next article LettersFull AccessCabergoline-Induced Psychosis in a Patient With Undiagnosed DepressionLouai Bilal, M.D., M.Sc., and Christopher Ching, Pharm.D.Louai BilalKaiser Permanente Behavioral Health CenterSearch for more papers by this author, M.D., M.Sc., and Christopher ChingKaiser Permanente Behavioral Health CenterSearch for more papers by this author, Pharm.D.Published Online:1 Oct 2012https://doi.org/10.1176/appi.neuropsych.11110348AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: Dopamine agonists bromocriptine and cabergoline are used in the medical treatment of prolactinomas.1 Emergence of psychotic symptoms is a more established association with bromocriptine treatment.2 With cabergoline it is reported once, and only in patients with known paranoid schizophrenia.3 Like other pro-dopaminergic agents, its potential to cause psychosis in patients with no history of psychosis is theoretically there, but not reported. The following is a case of cabergoline-induced psychosis in a woman with no prior psychiatric history of psychosis, who was being treated for a prolactinoma.A 44-year-old woman became convinced she was in an episode of the TV show “Hoarders.” She thought she saw a film crew from her apartment window and somehow inferred they wanted to harm her. She called 911 when she thought they infiltrated her apartment. When the police came, they took her to the psychiatric emergency room, not having found any evidence of people inside her apartment. Delusions and visual hallucinations had developed 1 week before admission. In the psychiatric unit, a detailed history uncovered that she had been being treated for a prolactinoma with cabergoline for 3 months. Before cabergoline, the patient was treated with bromocriptine, but this was changed because of complaints of lethargy.Cabergoline was stopped, and, without need to give an antipsychotic, all symptoms revolved within 48 hours of observation in the hospital. Review of psychiatric symptoms after resolution of psychosis uncovered some sadness, poor energy, passive suicidal thoughts, free-floating anxiety, excessive alcohol use, and a history of compulsive hoarding, with some frequent hand-washing, but no noted obsessions or other compulsions. Stressors included unemployment, social isolation, and breaking up with boyfriend of many years. She remembered feeling depressed for many years and not seeking any psychiatric treatment. She has a family history of attempted suicide in her father and completed suicide in an uncle. She accepted a referral to an intensive outpatient program and deferred starting any further treatment to that setting. The patient’s progress was monitored over 1 month after hospital discharge, and no symptoms of psychosis were noted.To our knowledge, this is the first reported case of cabergoline-induced psychosis in a patient with no previous history of psychosis. Our patient reported a history of long-standing untreated depression, compulsive hoarding, self-medicating with alcohol, and many psychosocial stressors. We wondered if patients with severe depression, in particular, constituted a clinical population who warrant careful monitoring when they are prescribed caberogoline because of fear of inducing psychosis. This, we feel, is a potentially important clinical situation that deserves further study.Kaiser Permanente Behavioral Health CenterNone of the authors have any relevant conflicts of interests to disclose.References1 Ali S, Miller KK, Freudenreich O: Management of psychosis associated with a prolactinoma: case report and review of the literature. Psychosomatics 2010; 51:370–376Crossref, Medline, Google Scholar2 Boyd A: Bromocriptine and psychosis: a literature review. Psychiatr Q 1995; 66:87–95Crossref, Medline, Google Scholar3 Chang SC, Chen CH, Lu ML: Cabergoline-induced psychotic exacerbation in schizophrenic patients. Gen Hosp Psychiatry 2008; 30:378–380Crossref, Medline, Google Scholar FiguresReferencesCited byDetailsCited ByTreatments of psychiatric disorders, hyperprolactinemia and dopamine agonistsBest Practice & Research Clinical Endocrinology & Metabolism, Vol. 379Treatment of Prolactinoma13 August 2022 | Medicina, Vol. 58, No. 8Start low, go slowly – mental abnormalities in young prolactinoma patients under cabergoline therapyJournal of Pediatric Endocrinology and Metabolism, Vol. 32, No. 9Asian Journal of Psychiatry, Vol. 31Archives of Endocrinology and Metabolism, Vol. 62, No. 2Clozapine Treatment for Cabergoline-Induced Psychosis in a Patient With a Giant ProlactinomaRodrigo Pérez-Esparza, M.D., M.Sc., Carlos Alberto Rojas-Guerrero, M.D., Gerson Geovany Andino-Rios, M.D., Patricia Arias-Garro, M.D., Jesús Ramírez-Bermúdez, M.D., Ph.D., Lesly Portocarrero-Ortiz, M.D., M.Sc.27 February 2017 | The Journal of Neuropsychiatry and Clinical Neurosciences, Vol. 29, No. 3Australian and New Zealand Journal of Obstetrics and Gynaecology, Vol. 56, No. 4Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology, Vol. 26, No. 2Gynecological Endocrinology, Vol. 31, No. 10Cabergoline2 March 2013 | Reactions Weekly, Vol. 1441, No. 1 Volume 24Issue 4 Fall 2012Pages E54-E54 Metrics None of the authors have any relevant conflicts of interests to disclose.PDF download History Published online 1 October 2012 Published in print 1 October 2012